Biotech Archives - Page 679 of 795

2 minute read

Catalyst Pharmaceuticals Announces FDA Approval Of Supplemental New Drug Application For FIRDAPSE Expanding Patient Population To Include Pediatric Patients 6 Years Of Age And Older

September 29, 11:20 AM

CORAL GABLES, Fla., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and

CPRX

1 minute read

Galecto’s Myelofibrosis Candidate Reduces Bone Marrow Fibrosis

By Vandana Singh

September 29, 11:17 AM

Galecto Inc (NASDAQ:GLTO) announced results from a planned intermediate assessment of its ongoing MYLOX-1 Phase 2a trial of GB2064 for myelofibrosis.…

GLTO

1 minute read

Regeneron-Sanofi’s Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis

By Vandana Singh

September 29, 9:54 AM

The FDA approved Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. With…

REGN

1 minute read

Idera Pharma Acquires Rare Disease Player, Names New CEO

By Vandana Singh

September 29, 9:52 AM

Idera Pharmaceuticals Inc (NASDAQ: IDRA) acquired Aceragen Inc, a privately-held biotechnology company focused on rare, orphan pulmonary, and rheumatic diseases.

IDRA

1 minute read

Panbela Receives Approvals To Open Trial Sites In Spain, France And Italy For ASPIRE Trial Studying Ivospemin In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Ductal Adenocarcinoma

By Benzinga Newsdesk

September 29, 9:08 AM

Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced Regulatory approval for the opening of

PBLA

1 minute read

Palisade Bio Announces Oral Presentation Of Phase 2 Data At The American College Of Surgeons Clinical Congress 2022 Oct 17

By Benzinga Newsdesk

September 29, 8:54 AM

Carlsbad, CA, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.(NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today

PALI

2 minute read

Butterfly Network Launches Proficiency Management Solution At American College Of Emergency Physicians Scientific Assembly 2022

By Benzinga Newsdesk

September 29, 8:46 AM

Enterprise imaging platform, Butterfly Blueprint™, now empowers emergency physicians, and other ultrasound users, to direct and manage ultrasound utilization and proficiency See Butterfly's New Proficiency

BFLY

1 minute read

Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud

By Vandana Singh

September 29, 8:40 AM

Aligos Therapeutics Inc (NASDAQ:ALGS) has filed a response to the complaint of and counterclaims against Janssen Biopharma. In November 2014, Johnson…

ALGS

2 minute read

SELLAS Life Sciences Presents Poster At 2022 SOHO Meeting Highlighting Bioequivalence Data For GFH009 Formulations

By Benzinga Newsdesk

September 29, 8:36 AM

GFH009 Formulation is Near Physiological pH, While Still Achieving Desired Effect - GFH009 at pH 6.0 Decreased Potential for Infusion Reaction and Made Dosing Better Tolerated After Multiple Doses or Long-time

SLS

1 minute read

FDA
News

Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation By FDA Of Investigational New Drug (IND) Application For NP-300, A Novel Drug Candidate For Symptomatic Relief And Treatment Of Diarrhea From Cholera And Other Pathogens

By Benzinga Newsdesk

September 29, 8:33 AM

Napo Pharmaceuticals, Inc. ("Napo"), the wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the activation by the U.S. Food and

JAGX